Clinical trial NCT05190770: A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer
Official title: A Randomized Phase II Double-Blinded Study of The Efficacy of Oleogel-S10 (AP101) Gel for the Treatment of Grade 2/3 Radiation Dermatitis in Breast Cancer Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Breast Cancer
Breast Cancer Stage
Breast Cancer Stage I
Breast Cancer Stage II
Breast Cancer Stage III
Breast Cancer Stage IV
Keywords: Radiation Dermatitis
PMRT
Breast cancer
Oleogel-S10
Triamcinolone acetonide
Memorial Sloan Kettering Cancer Center
21-091
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2022-01-13
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is find out whether Oleogel-S10 is an effective treatment for radiation dermatitis when it is used in combination with a standard wound treatment cream called triamcinolone. Oleogel-S10 has shortened the healing time for other types of skin wounds such as burns. Triamcinolone is a cream that is frequently used to treat moderate to severe skin conditions such as skin irritation caused by poison ivy, eczema, sunburn, and rashes.


Eligibility criteria: Inclusion Criteria:

* Patients who are receiving PMRT to the chest wall or post-lumpectomy RT to the whole breast cancer of any stage
* Age ≥ 18 years
* Patients who develop ARD grade 2/3 after fraction day 20 (when receiving 25 total fractions) or after fraction day 25 when receiving (30 total fraction inclusive of a 5 fraction boost) of radiation therapy with all locations of desquamation
* Able to self-administer topical interventions or provide for another person to apply the topical intervention
* Patients may be started on any topicals prior to study enrollment. Once patient is enrolled on study (on or before Day 1), patient must be able to discontinue other topicals (including topical steroids, Silvadene, calcineurin inhibitors) to the treatment area
* Patients have completed surgery or chemotherapy ≥ 4 weeks prior to start of radiation therapy. Patients may receive antibody-drug conjugates at any time before/during/after study
* Women of childbearing potential (WCBP) must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline (Day 0) and documented monthly.
* WCBP must agree to abstrain from sex or use a highly effective method of birth control\* from the time of consent through visit 5.

  * Adequate contraceptive methods include those with a low failure rate, i.e., less than 1% per year, when used consistently and correctly, such as abstinence from sexual intercourse, and some double barrier methods (condom with spermicide) in conjunction with use by the partner of an intrauterine device, diaphragm with spermicide, oral contraceptives, birth control patch or vaginal ring, or injectable or implanted contraceptives. Abstinence is acceptable only as true abstinence: when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

A woman that is postmenopausal (≥2 years since last menstrual period) or permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy) is not considered a WCBP.

Exclusion Criteria:

* Patients who are receiving radiation therapy for inflammatory breast cancer or malignant fungating wound
* Known history of allergy to any ingredient of the study medication
* Patients with collagen-vascular disease/vasculitis
* Patients receiving hypofractionated radiation therapy
* Special populations:

  * patients who, in the opinion of the investigator have a condition that precludes their ability to provide an informed consent

Primary outcomes:
measure: Reduction of radiation dermatitis grade 2-3 wound size from baseline to day 14 (+/- 3 days)
timeFrame: 14 days from baseline (+/- 3 days)
Secondary outcomes:
Other outcomes:
Locations:
city: Basking Ridge
country: United States
facility: Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)
state: New Jersey
city: Middletown
country: United States
facility: Memorial Sloan Kettering Monmouth (All protocol activities)
state: New Jersey
city: Harrison
country: United States
facility: Memorial Sloan Kettering Westchester (All Protocol Activities)
state: New York
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center (All Protocol Activities)
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Alina Markova, MD
role: PRINCIPAL_INVESTIGATOR
References: